Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Deltorphin
Overview
Deltorphin is a heptapeptide opioid agonist also derived from Phyllomedusa frog skin secretions, characterized by high selectivity for delta-opioid receptors. Like dermorphin, it contains an unusual D-amino acid residue that enhances metabolic stability and receptor affinity.
Mechanism of Action
Deltorphin exhibits analgesic properties distinct from mu-opioid agonists, with reduced respiratory depression and addiction liability in animal models. It has served as a pharmacological tool to elucidate delta-opioid receptor physiology and potential therapeutic roles.
Research Summary & Key Findings
Animal studies have shown potent antinociceptive effects with a more favorable side effect profile compared to morphine, particularly regarding respiratory suppression. Deltorphin analogs have been investigated to develop more stable and blood-brain barrier permeable compounds. Clinical translation has not occurred, and current use is limited to preclinical research applications.
Clinical Status
Deltorphin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Deltorphin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Deltorphin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Deltorphin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Pain
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone...
View detailsDifelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing periphera...
View detailsARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the inna...
View detailsPalmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to ti...
View detailsNo lawful pathway today
Deltorphin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.